Great Basin Scientific, a US-based life sciences company that counts electronics manufacturer Hitachi has one of its investors, has raised just over $8m in its initial public offering.
Great Basin commercialises technologies for the molecular diagnostic testing market. It sold 1.15 million shares priced at $7.00 each.
The proceeds will be used for sales and marketing, research and development, the development of new tests for Group B Strep, and to manufacture analysers it provides to customers free of charge.
The company had secured approximately $35.8m in equity funding, including $7.6m from a series D round in April, in which Hitachi Chemical invested $3.5m.
Hitachi’s stake was diluted from 18.5% to 13.8% in the offering, while other shareholders in the company include holding vehicle Krispen Family Holdings, which owns a 10.7% share, and investment firm Onset Financial, which holds 4.6%.
Dawson James Securities is the sole book-running manager for the IPO and Newbridge Securities is serving as co-manager. They have the option to buy another 173,000 shares priced at $6.43, which would increase the size of the offering to almost $9.3m.